

# NICEATM Update: ICCVAM Public Forum 2024

Nicole C. Kleinstreuer, PhD

Director, NTP Interagency Center for the Evaluation of Alternative Toxicological Methods

Executive Director, Interagency Coordinating Committee for the Validation of Alternative Methods



## **Announcement!**

## ICCVAM Participating Agencies Update 18 Participating Agencies

- Consumer Product Safety Commission
- Department of Agriculture
- Department of the Interior
- Department of Transportation
- Environmental Protection Agency
- Food and Drug Administration
- Occupational Safety and Health Administration
- National Institute for Occupational Safety and Health
- Agency for Toxic Substances and Disease Registry
- National Cancer Institute
- National Center for Advancing Translational Sciences (since 2024)

- National Inst of Environmental Health Sciences
- National Library of Medicine
- National Institutes of Health
- Department of Defense
- Department of Energy
- National Institute of Standards and Technology (since 2017)
- Dept of Veterans Affairs Office of Research and Development (since 2020)
- Other participants
  - Tox21
  - NCATS



### **Recent NCATS Collaborations**

Toxicology in Vitro 91 (2023) 105630

Contents lists available at ScienceDirect







Frontiers in Toxicology

TYPE Original Research PUBLISHED 28 February 2024 DOI 10.3389/ftox.2024.1321857

### Parallel evaluation of a skin for dermal absorpt

Alec T. Salminen<sup>a</sup>, Kelly J. Da Frederick A. Beland a, Kristy I Nicole C. Kleinstreuer<sup>8</sup>, Jonat Menghang Xia<sup>d</sup>, Suzanne C. F

- <sup>a</sup> Division of Biochemical Toxicology, National Center
- <sup>b</sup> Toxicologic Pathology Associates, Jefferson, AR, U
- <sup>c</sup> Office of Scientific Coordination, National Center t
- <sup>1</sup> National Center for Advancing Translational Scien
- <sup>a</sup> Center for Drug Evaluation and Research, U.S. Foo
- Center for Food Safety and Applied Nutrition, U.S.
- <sup>8</sup> National Toxicology Program Interagency Center fo Triangle Park, NC, USA
- <sup>h</sup> Center for Veterinary Medicine, U.S. Food and Dru



#### **OPEN ACCESS**

EDITED BY

Maia Aleksic.

Unilever, United Kingdom

Mesha Williams.

Unilever, United Kingdom

Marlene Thai Kim,

United States Food and Drug Administration,

**United States** 

Martyn Chilton,

Lhasa Ltd., United Kingdom

\*CORRESPONDENCE

Menghang Xia,

Zhengxi Wei,


with in silico analysis to identify

Use of in vitro methods combined

**Development and Validation of Enzyme-Based CYP26A1 Inhibition Assay** in a High-Throughput Screening Platform


Srilatha Sakamuru<sup>1</sup>, Dongping Ma<sup>2</sup>, Jocylin D. Pierro<sup>3</sup>, Nancy C. Baker<sup>4</sup>, Nicole Kleinstreuer<sup>5</sup>, James J. Cali<sup>2</sup>, Thomas B. Knudsen<sup>3</sup>, Menghang Xia<sup>1</sup>

Retinol ←



Retinal reductase

Retinoic acid signaling pathway and its metabolism





Transcription

Abstract #3015

**National Center** 





## **Integrated Chemical Environment**



- Curated in vivo, in vitro, and in silico toxicity data
- Measured and predicted chemical properties
- Predicted exposure
- Reported and predicted chemical use categories

#### The data are used across ICE tools.











Chemical Character ization

- Explore ICE data through interactive visualizations
- · Identify structurally similar chemicals
- Leverage computational models without coding

Inter-connectivity: Send chemical and assay selections between tools.



- Reference and Non-reference chemical lists
- Support the development and evaluation of new test methods





- Exposure data added to REST API
- Functional use data set and its exploration through chemical characterization tool
- New chemical quick lists: Mixtures and Formulations in ICE and <u>ToxCast</u> Phase I, Phase II, and e1k
- · Search tool UI and visualization updates

ICE v4.0.2 (March 2024)

- · cHTS updated to invitrodb v3.5
- Technological interference flags added to cHTS pipeline and applied to Curve Surfer tool result cards
- · Additional ACC overlay option provided in Curve Surfer tool result visualizations
- · Additional Search tool UI and visualization updates

ICE v4.1 (August 2024)

- Update cHTS annotations from NCI Metathesaurus to OBO Foundry
- . New PFAS chemical quick list and updated ROC chemical quick list
- . ICE REST API updated to include Curve Surfer tool raw data
- Additional data visualizations in Search tool

Future Updates

- Update cHTS pipeline to integrate invitrodb v4.1
- Option to use custom ADME parameters to run PBPK/IVIVE
- · Ongoing search visualization updates

### Contributors



#### Subscribe to NICEATM News

https://ntp.niehs.nih.gov/go /niceatm














https://ice.ntp.niehs.nih.gov/



## Mapping Tox21/ToxCast assays on Key Characteristics of Carcinogens





Mapping

**KCC1:** Is Electrophile or can be Activated to Electrophiles

KCC2: Induces DNA Damage response

KCC3: Activates Mutagenic DNA Repair & Promotes

Genomic Instability

**KCC4:** Induces Epigenetic Alterations

**KCC5:** Induces Oxidative stress

**KCC6:** Induces Chronic Inflammation

KCC7: Is Immunosuppressive

KCC8: Modulates Receptors-mediated effects

KCC9: Causes Immortalization


KCC10: Alters Cell Proliferation, Cell Death or

**Nutriment Supply** 

- ~ 9000 unique chemicals
- ~ 2000 assays

Expert working group including ~20 people from NICEATM, EPA, NIEHS ROC, IARC, U. Berkely, Texas A&M University


## Developing Al workflow for carcinogenicity prediction





## **Bio/Chemical Database Assembly**

THINKING ABOUT YOUR CURRENT JOB, HOW MUCH OF YOUR TIME IS SPENT IN EACH OF THE FOLLOWING TASKS?



45% of data analysts time is spent loading and cleaning data



# BioBricks.ai Faster Informatics

```
$ biobricks install tox21
$ python
>>> import biobricks, pandas
>>> tx21 = biobricks.load('tox21')
>>> tx21.tox21.read().load()
```



```
NICEATM & BioBricks
Partnership:
NSF ProtoOKN
```

```
# NCGC00256074-01 tox21-ache-p3 ... OCC(=0)OCCCC ...
# NCGC00255047-01 tox21-ache-p3 ... Nc1ccc(cc1)C(=0)OCC ...
# [2075022 rows x 19 columns]
```

## **OPERA models (version 2.9)**

Phys	chem properties	Chemicals	Version
ВР	<b>Boiling Point</b>	7860	<mark>2.9</mark>
HL	Henry's Law Constant	2233	<mark>2.9</mark>
LogP	Octanol-water Partition Coefficient	18154	<mark>2.9</mark>
MP	<b>Melting Point</b>	22554	<mark>2.9</mark>
VP	Vapor Pressure	6764	<mark>2.9</mark>
ws	<b>Water Solubility</b>	9943	<mark>2.9</mark>
рКа	Acid Dissociation Constant	6503	2.6
KOA	Octanol/Air Partition Coefficient	270	2.6


Envir	onmental fate	Chemicals	Version
АОН	Atmospheric Hydroxylation Rate	692	2.6
BCF	Bioconcentration Factor	626	2.6
BioHL	Biodegradation Half-life	150	2.6
RB	Ready Biodegradability	1603	2.6
KM	Fish Biotransformation Half-life	541	2.6
кос	Soil Adsorption Coefficient	728	2.6

Toxic	ity endpoints	Chemicals	Version
ER	Estrogen Receptor Activity	32464	2.6
AR	Androgen Receptor Activity	47673	2.6
AcuteTox	Acute Oral Systemic Toxicity	50660	2.6

ADM	properties	Chemicals	Version
FUB	Fraction unbound	3229	2.8
Clint	Intrinsic clearance	1346	2.8
CACO2	Caco-2 permeability	4601	2.8


### **OPERA on GitHub**

### Source code



https://github.com/NIEHS/OPERA

### **Packaged installers**




https://github.com/NIEHS/OPERA/releases

### Over 7000 downloads

(https://tooomm.github.io/github-release-stats/)



## **OPERA** predictions online





### **OPERA and ICE Used Worldwide**



Open Access
This article is licensed under CC-BY 4.0 © (1)

pubs.acs.org/est

rticle

## Two-Stage Machine Learning-Based Approach to Predict Points of Departure for Human Noncancer and Developmental/Reproductive Effects

Jacob Kvasnicka, Nicolò Aurisano, Kerstin von Borries, En-Hsuan Lu, Peter Fantke, Olivier Jolliet, Fred A. Wright, and Weihsueh A. Chiu\*




Cite This: https://doi.org/10.1021/acs.est.4c00172




#### **ACCESS** I

III Metrics & More

Article Recommendations



ABSTRACT: Chemical points of departure (PODs) for critical health effects are crucial for evaluating and managing human health risks and impacts from exposure. However, PODs are unavailable for most chemicals in commerce due to a lack of *in vivo* toxicity data. We therefore developed a two-stage machine learning (ML) framework to predict human-equivalent PODs for oral exposure to organic chemicals based on chemical structure. Utilizing ML-based predictions for structural/physical/chemical/toxicological properties from OPERA 2.9 as features (Stage 1), ML models using random forest regression were trained with human-equivalent PODs derived from *in vivo* data sets for general noncancer effects (n = 1,791) and reproductive/developmental effects (n = 2,228), with robust cross-validation for feature selection and estimating



generalization errors (Stage 2). These two-stage models accurately predicted PODs for both effect categories with cross-validation-based root-mean-squared errors less than an order of magnitude. We then applied one or both models to 34,046 chemicals expected to be in the environment, revealing several thousand chemicals of *moderate* concern and several hundred chemicals of *high* concern for health effects at estimated median population exposure levels. Further application can expand by orders of magnitude the coverage of organic chemicals that can be evaluated for their human health risks and impacts.

KEYWORDS: QSAR model, machine learning, toxicity prediction, chemical risk assessment, high-throughput screening, life cycle impact assessment (LCIA)


- OPERA predicted properties used as features in ML model to predict PODs for thousands of chemicals
- US EPA SEEM3 exposure data downloaded from ICE to facilitate comparisons








## **QSAR-ready standardization tool**



GitHub: <a href="https://github.com/NIEHS/QSAR-ready/releases">https://github.com/NIEHS/QSAR-ready/releases</a>

KNIME Hub: https://kni.me/w/\_iyTwvXi6U3XTFW1

Docker Hub: <a href="https://hub.docker.com/r/kamelmansouri/qsar-ready">https://hub.docker.com/r/kamelmansouri/qsar-ready</a>



Mansouri, K. et al. Free and open-source QSAR-ready workflow for automated standardization of chemical structures in support of QSAR modeling. J <u>Cheminform</u> 16, 19 (2024). https://doi.org/10.1186/s13321-024-00814-3




## **Application of CaTMOS to Pesticide Als**

ELSEVIER

## **EPA Case Study**

- Comparative analysis of 177
   pesticides with LD<sub>50</sub> data between
   CaTMOS and EPA database
- 88% categorical concordance for 165 chemicals with empirical in vivo LD<sub>50</sub> values ≥ 500 mg/kg

Toxicity Category based on CATMoS Prediction	Number of predictions	Toxicity Category based on Empirical <i>In Vivo</i> Test Data			
	-	I	II	III	IV
I (<50 mg/kg)	2	-	1	1	-
II (50-500 mg/kg)	25	-	6	16	3
III (>500-5,000 mg/kg)	126	-	5	62	59
IV (>5,000 mg/kg)	24	-	-	5	19
III and IV combined	150	-	5	14	45



Regulatory Toxicology and Pharmacology 149 (2024) 105614

Contents lists available at ScienceDirect

Regulatory Toxicology and Pharmacology


Regulatory Toxicology and Pharmacology

journal homepage: www.elsevier.com/locate/yrtph




Evaluation of *in silico* model predictions for mammalian acute oral toxicity and regulatory application in pesticide hazard and risk assessment


Patricia L. Bishop <sup>a,\*</sup>, Kamel Mansouri <sup>b</sup>, William P. Eckel <sup>c</sup>, Michael B. Lowit <sup>c</sup>, David Allen <sup>d,1</sup>, Amy Blankinship <sup>c</sup>, Anna B. Lowit <sup>e</sup>, D. Ethan Harwood <sup>c</sup>, Tamara Johnson <sup>c</sup>, Nicole C. Kleinstreuer <sup>b</sup>



## **Acute Inhalation Toxicity Database**

Data Source	Data Records	Unique Substances
Legacy data from ChemIDplus (now integrated into PubChem)	2036	1249
National Institute for Occupational Safety and Health Pocket Guide	136	649
European Chemicals Agency Registration, Evaluation, <u>Authorisation</u> and Restriction of Chemicals Database	3016	611
U.S. Environmental Protection Agency Acute Exposure Guideline Levels	1682	271
U.S. Department of Defense	47	13







- 1025 unique chemicals
- ~760 chemicals will be used to support a collaborative modeling effort
- The database can be downloaded and explored on ICE



Download the Rat Acute Inhalation Database from ICE. https://ice.ntp.niehs.nih.gov/ DATASETDESCRIPTION




## Modeling and Visualization (MoVIZ) Pipeline





## **Chemical Grouping Workflow**





## **Machine Automating Study Data Curation**


### Identification





### **Extraction**



## **Annotation**








- Important for leveraging high-quality studies in the published literature
- Applications in systematic review of chemical effects
- Establishing reference datasets for validating new methods




## **LLMs to Extract Study Information**






## **User Friendly DASS App**





DA ITS h- CLAT Score	DA ITS DPRA : Score	DA ITS in : Silico Score	DA ITS Total : Score	DAITS :	DAITS :
0	3	1	4	1	18
0	0	NA.	0	0	NC
2	0	1	3	1	18
1	1	1	3	1	18
0	0	1	- 1	0	NC
0	0	0	0	0	NC
2	3	1	6	1	1A
2	3	1	6	1	1A
3	3	1	7	1	1A
2	0	1	3	1	18






DASS App https://ntp.niehs.nih.gov/ go/952311

#### Confusion Matrix and Performance Metrics

Reference Column: reference\_hppt\_call Prediction Column: DA ITS Call

	[	Reference	
	[	Positive	Negative
	Positive	50	5
Predicted	Negative	3	6
	Inconclusive	2	0

Metric	Value
N	66
Accuracy	85%
Balanced Accuracy	73%
F1 Score	93%
True Positive Rate	91%
False Positive Rate	45%
True Negative Rate	55%
False Negative Rate	5%





## **HPPT Database and papers**

Home » What We Study » NICEATM: Alternative Methods » Test Method Evaluations » Identification of Skin Sensitizers » Human Skin Sensitization Data

https://ntp.niehs.nih.gov/go/hppt 🔄

Skin Sensitizers

Human Skin Sensitization Data

Isothiazolinones Risk Assessment

Electrophilic Allergen Screening Assav

**Defined Approaches** 

**Evaluations of the LLNA** 



### Human Data for Skin Sensitization Method Evaluation

Establishing confidence in alternatives to animal use for identifying potential skin sensitizers requires high-quality reference data for evaluation of new approaches. As humans are the species of interest for regulatory testing, the ideal reference data will be derived from testing on humans.

To support the evaluation of non-animal approaches for skin sensitization assessment, <a href="NICEATM">NICEATM</a> and the <a href="German Federal Institute for Risk">German Federal Institute for Risk</a> Assessment or (BfR) collected data from 1555 publications for 2277 human predictive patch tests (HPPTs). Data from two types of HPPT were included: the human repeat insult patch test and the human maximization test. Tests were scored for reliability and traced back to their original reports to remove duplicates. The resulting database contains information for 1366 unique substances. This database has been described in a publication (<a href="Strickland et al. 2023">Strickland et al. 2023</a>) and is being made available to serve as a resource for additional evaluation of alternative methods and development of new approach methodologies for skin sensitization assessments. Users may download the database in Excel format via the link below. Data are also available via NICEATM's <a href="Integrated Chemical Environment">Integrated Chemical Environment</a>.

Human predictive patch test database (updated May 25, 2023)

https://ntp.niehs.nih.gov/whatwestudy/niceatm/test-method-evaluations/skin-sens/hppt

Archives of Toxicology (2023) 97:2825–2837 https://doi.org/10.1007/s00204-023-03530-3

#### **REVIEW ARTICLE**



#### A database of human predictive patch test data for skin sensitization

```
Judy Strickland 1 . Jaleh Abedini 2 · David G. Allen 2 · John Gordon 2 · Victoria Hull 0 · Nicole C. Kleinstreuer 3 · Hon-Sum Ko 4 · Joanna Matheson 2 · Hermann-Josef Thierse 1 · James Truax 1 · Jens T. Vanselow 6 · Matthias Herzler 5
```

Archives of Toxicology (2024) 98:1253-1269 https://doi.org/10.1007/s00204-023-03656-4

#### **REVIEW ARTICLE**



## Use of human predictive patch test (HPPT) data for the classification of skin sensitization hazard and potency

Matthias Herzler<sup>1</sup> • Jaleh Abedini<sup>2</sup> • David G. Allen<sup>2</sup> • Dori Germolec<sup>3</sup> • John Gordon<sup>4</sup> • Hon-Sum Ko<sup>5</sup> • Joanna Matheson<sup>4</sup> • Emily Reinke<sup>2</sup> • Judy Strickland<sup>2</sup> • Hermann-Josef Thierse<sup>1</sup> • Kim To<sup>2</sup> • James Truax<sup>2</sup> • Jens T. Vanselow<sup>1</sup> • Nicole Kleinstreuer<sup>6</sup>

- As part of TG 497 development, a highly curated human predictive patch test database was developed
- Database published in 2023, available on NICEATM website
- Proposed HPPT GHS classification approach, utilizing a dose descriptor, published in 2024
- Manuscript evaluating HPPT variability is under development
- HPPT App (Rshiny tool) under development


## Environmental Health Sciences The Skin Allergy Risk Assessment (SARA) – ICE Model



- SARA originally developed by Unilever as a defined approach for skin allergy risk assessment
  - A Bayesian statistical model which infers a human-relevant metric of sensitiser potency (termed ED<sub>01</sub>), the dose with a 1% chance of human skin sensitisation.
    - Accounts for variability of the input data and explicitly quantifies uncertainty.
  - SARA-ICE is an expansion of the original SARA model, with increased database, input data types and a refined output.
    - Utilises any combination of human repeat insult patch test (HRIPT), LLNA, direct peptide reactivity assay (DPRA), KeratinoSens(TM), h-CLAT, U-SENS(TM) data.
    - Added GHS classification parameters

SARA-ICE is on the OECD workplan for inclusion in TG 497, the Defined Approaches for Skin


Sensitization







### The SARA – ICE Model Container



Model has been packaged for download and local implementation. The beta version is currently available for testing and evaluation upon request (email <a href="mailto:Emily.reinke@inotivco.com">Emily.reinke@inotivco.com</a> for access)




## Electrophilic Allergen Screening Assay

(EASA)

- Addresses KE1 in the Skin Sensitization AOP
- In chemico plate-based assay
  - Measures protein reactivity of a chemical via fluorescent or colorimetric probes
- Multi-lab validation study
  - Participating labs: U.S. FDA, DoD, CPSC/NIST, BRT, Inc.
  - Utilize 2019 OECD\* Performance Standards for KE1-based assays for validation study
  - Peer Review of validation study underway
- Accepted on to 2024 OECD workplan for inclusion in TG 442C

Lab #	Balanced Accuracy	Sensitivity	Specificity	Within Lab Reproducibility	Between Lab Reproducibility
1	76%	85%	67%	94%	
2	82%	92%	71%	100%	
3	84%	85%	83%	97%	96%
4	84%	85%	83%	94%	
Mean	82%	87%	76%	96%	






## DAs for Predicting Eye Irritation Classifications

NICEATM, PETA Science Consortium International, and EPA Office of Pesticide Programs collaborated to test agrochemical formulations in a multi-phase study using a common set of in vitro test methods.

### **EPA**

- Developed two DAs involving:
  - BCOP with histopathology
  - EO + BCOP with histopathology
- Compared predictions (and associated personal protective equipment requirements) of the DAs and in vivo data orthogonally, rather than evaluating direct concordance.
  - Good alignment with many discrepancies corrected if only considering personal protective equipment.
- Weight of evidence evaluation
  - Suggests both DAs are as or more fit-for-purpose, reliable, and relevant than the in vivo test.
  - Overall high confidence in use of DAs for assessing eye irritation potential of agrochemical formulations.
- Publication: van der Zalm et al. 2024 https://doi.org/10.1080/15569527.2023.2275029






## DAs for Predicting Eye Irritation Classifications

### **GHS**

- Preliminary assessment of results to determine consensus predictions for each formulation (i.e., majority agreement on classification among in vitro methods and historical in vivo data).
  - Consensus prediction achieved for 27 of 29 formulations.
- Developed four DAs:
  - BCOP with histopathology (DA-BCOP+)
  - EO + BCOP with histopathology (DA-EO+)
  - TTL+ BCOP with histopathology (DA-TTL+)
  - EyeIRR-IS + BCOP with histopathology (DA-EyeIRR-IS+)
- Assessed DA predictions (and associated hazard labeling) for concordance with consensus predictions, rather than direct concordance with in vivo data.
  - In vivo test concordant or no change to hazard labeling for 93% (25/27) of formulations.
     Remaining 7% underpredicted and underprotective.
  - All DAs performed similarly or better than the in vivo test, and generally resulted in hazard labeling that is more protective of human health.
- Manuscript in final stages of preparation (anticipate publishing in summer 2024).









# Predicting Chemical Distribution in Brain and Adipose Compartments


### Ongoing Updates

- Incorporation of predicted BBB permeability coefficient values in addition to measured.
- Exploration of additional validation criterions applied for other commercial brain models.
- Efforts for further comparisons using pharmacokinetic time series data from additional chemicals to provide greater confidence in these models.







- Diffusion-Limited brain compartment considering blood brain barrier permeability (Complex Model)
- Predicts brain tissue distribution of chemicals from capillary blood



Model output includes time series concentration graphs





 Perfusion-limited model with brain and adipose compartments (Simple Model)


 Build upon generic PBPK model from EPA's <a href="https://https:/



# In Vitro to In Vivo Extrapolation (IVIVE) for Developmental Neurotoxicity

## A Comparison of Physiologically Based Pharmacokinetic Models


- Physiologically-based pharmacokinetic (PBPK) models compared for DNT-IVIVE approach
- Chemicals bioactive in DNT NAMs from EPA with experimental toxicokinetic data
- Findings
  - Chemicals preferentially partition into the brain
  - In vivo DNT points of departure fall within the range of human administered equivalent dosages (AEDs) for bioactive endpoints for both programs, showing the concordance of in vitro-derived, DNT-IVIVE predictions with in vivo data
  - GastroPlus & httk perform similarly, though httk provides somewhat more conservative estimates




## Transferability of the DNT in vitro battery

## Identification of training set chemicals

- Developmental Neurotoxicity (DNT) in vitro battery (IVB)
  - 17 assays
  - Endorsement & initial recommendations provided by OECD in 2023
- Training set chemicals are needed for assay transferability
  - Initial lists were provided here
    - Assay-developed recommendations- original publications & OECD guidance
    - Data-driven recommendations- selective activity identified in ToxCast
    - Negative compounds
- Lists are being provided to OECD this month









## **DNT Health Effect Innovation (HEI) Program**

## Supporting screening efforts in the OECD DNT IVB



Phase II: 108 chemicals




Testing projected to be finalized late summer

Phase III: ~120 chemicals Selection process in final stage, projected to be finalized this summer



## Integrated Approach to Testing and assessment (IATA) for DNT

### Selected Compounds Based on Prioritization



### Mifepristone (RU486)

Negative in OECD guidance document but considered unfavorable after further evaluation

### Pyraclostrobin


Known MoA (inhibiting mitochondrial respiration) known to be sensitive to brain development

Manuscript in preparation to be submitted in the fall



https://ice.ntp.niehs.nih.gov/


### Systematic Review (EFSA protocol)




sysrev

In vitro effects: effects on proliferation and differentiation of NPCs, and on density of dendritic spines
In vivo effects: included decreased dopaminergic neurons, change in behavior, and memory impairment

#### Mifepristone




Targets




## Identifying Seizure-Inducing Biological Targets

#### Uncovering Targets and Assays Related to Seizures




### Assessing Seizure-Related Reference Compounds from Literature in Established Databases








### Seizure AOP Network Based on the AOP-Wiki




Manuscript in preparation to be submitted shortly

### **Chemical Diversity Among Reference Chemicals**





### **Heatmap with Tested Chemicals in Identified Seizure Assays**





### **Methods2AOP International Consortium**





### Stakeholder feedback

**Discussion, Instructions for Breakout groups** 





Hogberg, Helena, NIEHS

all

all





### Workshop Agenda

**Breakout Groups** 

Wrap up, decisions, next steps

Торіс	Speaker/Moderator
Welcome and introduction	Wittwehr, Clemens, JRC
AOPs and regulatory decisions - introduction	Terron, Andrea, EFSA
Real life example: AOP Applications in the US EPA Endocrine Disruptor Screening Program	<b>Lynn</b> , Scott, EPA
Q&A	moderation: Batista, Sofia, EFSA
Why Methods2AOP?	Wittwehr, Clemens, JRC
Break	
Transformations Underway in the AOP-Wiki to Advance NAMs	Hench, Ginnie, RTI
Case study: Aromatase inhibition leading to Reproductive Dysfunction	Villeneuve, Dan, EPA

Manuscript in preparation to be submitted shortly



## Inter-laboratory Pre-validation Study of Human Thyroid Microtissue Assay





TOXICOLOGICAL SCIENCES, 2019, 1-16


doi: 10.1093/toxxxi/kfz238 Advance Access Publication Date: December 6, 2019 Research Article


### Development of an *In Vitro* Human Thyroid Microtissue Model for Chemical Screening


Chad Deisenroth , \*1 Valerie Y. Soldatow, † Jermaine Ford, † Wendy Stewart, \*Cassandra Brinkman, \*Edward L. LeCluyse, †Denise K. MacMillan, †and Russell S. Thomas \*


















### **Team Members**

### **Coordinator: NICEATM**



### **Status:**

- Phase 1.2 complete (initial transfer phase, lab 2)
- Phase 1.3 underway (secondary transfer phase, labs 3 and 4)
- Phase 1.4 slated to start in summer (validation study)

### National Institute of **Environmental Health Sciences** Division of Translational Toxicology

PublMed

Databases

**₩ DistillerSR** 


## Cardiovascular (CV)

## **Health Effect Innovation (HEI) Program**


## Systematic Evidence Mapping and

Computational Modeling for **CV** Risk

Integrating HTS assay data and exposure















QSAR models for













**Search Strategy Terms** 



## Risk Characterization of Triazole Fungicides using Human Biomonitoring and Mechanistic Data

## Sampling










Biomarkers



**Urinary Triazoles** 

Internal Dose Indicator

Oxidative Stress Markers



Plasma Bile Acids

Liver Enzymes


Steroid Hormones




Cytome assay – Genotoxicity

### Risk Calculations

HQ Calculation at the highest quantified value:







Costa, et al. Chem Biol Interact. 2023;383:110689.





## Association of *in vitro* molecular targets and human biomarker alterations






### **Concentration-Response Curves**


cHTS data from Tox21/ToxCast



### In Vitro to In Vivo Extrapolation

- Calculate equivalent doses from cHTS data
- Comparison with human exposure








## **Area of Focus: NAMs to Address PopVarSusc**

# Using New Approach Methodologies to Address Variability and Susceptibility Across Populations



https://ntp.niehs.nih.gov/go/popvar

Workshop report in prep to be submitted to Human Genomics shortly



**Human Genomics** 





**Human Genomics Call for Papers** 

New Approach Methodologies to Address Population Variability and Susceptibility in Human Risk Assessment

Guest Editors: Helena Hogberg, PhD; Nicole Kleinstreuer, PhD; Kim To, PhD

Submission Status: Open | Submission Deadline: 30 June 2024



https://www.biomedcentral.com/collections/NAMAPVS





## Clustering and Classification Workshop

Workshop report under revision at EHP

Convened international experts to discuss methods, their applications to guide toxicology research and inform hazard and risk assessment.

### **Accomplishments:**

- Defined the concept similarity for supervised and unsupervised approaches
- •Introduced different approaches, corrected some misconceptions
- Involved both NAM developers and users
- •Established a consortium and a community for increasing communication and collaboration across sectors
- Ongoing and future: develop and share new ideas/concepts (best practices & innovation)

https://www.niehs.nih. gov/news/events/past mtg/2022/nams2022/i ndex.cfm







## Workshop on NAMs for the Gastrointestinal Tract October 11-12, 2023

Workshop report to be submitted to ALTEX

An in-person workshop to examine the state of the science for NAMs modeling the gastrointestinal tract and their context for regulatory consideration.

- Focal Areas:
  - General "state of the science" for NAM gut models
  - Models for de-risking chemicals for systemic toxicity (regulatory relevance and application)
  - Gastrointestinal toxicity
  - Systemic absorption and distribution
  - Gut allergenicity
- A webinar series to provide background information took place prior to workshop (September 2023)
- In-person Day 1: Scientific talks/state of the science
- In-person Day 2: Breakout groups covering the following themes:
  - Establishing confidence in existing models
  - Strengths and limitations of different model systems





## Acknowledgments

## The NICEATM Group



## **NIEHS/DTT Contributors**





https://ntp.niehs.nih.gov/go/ 2021iccvamreport



Subscribe to NICEATM
News email list





Coming Soon: 2022 – 2023 Biennial Report